LUNGevityKristin Posted December 5, 2019 Share Posted December 5, 2019 "AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) and granted Priority Review for IMFINZI in combination with standard-of-care (SoC) chemotherapy (etoposide with either cisplatin or carboplatin) for the treatment of patients with previously untreated extensive-stage small cell lung cancer (SCLC). A Prescription Drug User Fee Act (PDUFA) date is set for the first quarter of 2020...." Read the whole article here: https://www.astrazeneca-us.com/content/az-us/media/press-releases/2019/imfinzi-durvalumab-granted-fda-priority-review-for-the-treatment-of-patients-with-extensive-stage-small-cell-lung-cancer-12022019.html Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.